Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 1088-1097

  Chen, Z Y ^a   Raghav, K ^b   Lieu, C H ^c   Jiang, Z Q ^b   Eng, C ^b   Vauthey, J N ^d   Chang, G J ^d   Qiao, W ^d   Morris, J ^d   Hong, D ^d   Hoff, P ^e   Tran, H ^d   Menter, D G ^b   Heymach, J ^d   Overman, M ^b   Kopetz, S ^b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

angiogenesis; cytokine; growth factors; inflammation; metastatic colorectal cancer; neutrophil lymphocyte ratio; survival

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2RALPHA; INTERLEUKIN 6; INTERLEUKIN 8; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CLUSTER ANALYSIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; COHORT ANALYSIS; COLORECTAL NEOPLASMS; IMMUNOLOGY; LYMPHOCYTE; METASTASIS; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PROCEDURES; PROGNOSIS;

ADULT; AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84925335444     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.61     Document Type: Article

References (47)

1. Absenger G, Szkandera J, Stotz M, Postlmayr U, Pichler M, Ress AL, Schaberl-Moser R, Loibner H, Samonigg H, Gerger A (2013) Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Res 33(10): 4591-4594.
2. Bandapalli OR, Ehrmann F, Ehemann V, Gaida M, Macher-Goeppinger S, Wente M, Schirmacher P, Brand K (2012) Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine 57(1): 46-53.
3. Bisgin A, Kargi A, Yalcin AD, Aydin C, Ekinci D, Savas B, Sanlioglu S (2012) Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer 12: 58.
4. Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407): 330-337.
5. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7): 1073-1081.
6. Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339(6117): 286-291.
7. Diakos CI, Charles KA, McMillan DC, Clarke SJ (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15(11): e493-e503.
8. Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323(18): 1228-1233.
9. Emoto K, Yamada Y, Sawada H, Fujimoto H, UenoM, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y (2001) Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92(6): 1419-1426.
10. Erreni M, Mantovani A, Allavena P (2011) Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron 4(2): 141-154.
11. Galamb O, Wichmann B, Sipos F, Spisak S, Krenacs T, Toth K, Leiszter K, Kalmar A, Tulassay Z, Molnar B (2012) Dysplasia-carcinoma transition specific transcripts in colonic biopsy samples. PLoS One 7(11): e48547.
12. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6): 883-899.
13. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013a) The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol 88(1): 218-230.
14. Guthrie GJ, Roxburgh CS, Richards CH, Horgan PG, McMillan DC (2013b) Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. Br J Cancer 109(1): 131-137.
15. Inoue Y, Iwata T, Okugawa Y, Kawamoto A, Hiro J, Toiyama Y, Tanaka K, Uchida K, Mohri Y, Miki C, Kusunoki M (2013) Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology 84(2): 100-107.
16. Jurgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer 108(6): 1316-1323.
17. Kantola T, Klintrup K, Vayrynen JP, Vornanen J, Bloigu R, Karhu T, Herzig KH, Napankangas J, Makela J, Karttunen TJ, Tuomisto A, Makinen MJ (2012) Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 107(10): 1729-1736.
18. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3): 614-622.
19. Knupfer H, Preiss R (2010) Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Colorectal Dis 25(2): 135-140.
20. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K, Inoue Y, Kusunoki M (2008) Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 98(7): 540-544.
21. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3): 453-459.
22. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, Lv Y (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134(10): 2403-2413.
23. Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14(6): e218-e228.
24. Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ, Conti A, Tancini G (1990) The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer 26(1): 33-36.
25. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203): 436-444.
26. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers AB, Moroski-Erkul CA, McFaline JL, Schauer DB, Dedon PC, Fox JG, Samson LD (2008) DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 118(7): 2516-2525.
27. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J (2011) Histopathologicbased prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6): 610-618.
28. Motomura T, Shirabe K, Mano Y,Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y (2013) Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 58(1): 58-64.
29. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W, Dabrowski A, Szmitkowski M (2007) Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 380(1-2): 208-212.
30. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Alliance for Clinical Trials In O (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19(24): 6957-6966.
31. Ohchi T, Akagi Y, Kinugasa T, Kakuma T, Kawahara A, Sasatomi T, Gotanda Y, Yamaguchi K, Tanaka N, Ishibashi Y, Miyamoto S, Kage M, Shirouzu K (2012) Amphiregulin is a prognostic factor in colorectal cancer. Anticancer Res 32(6): 2315-2321.
32. Paramanathan A, Saxena A, Morris DL (2014) A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 23(1): 31-39.
33. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G (2013) Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13: 49.
34. Pinato DJ, Stavraka C, Flynn MJ, Forster MD, OCathail SM, Seckl MJ, Kristeleit RS, Olmos D, Turnbull SJ, Blagden SP (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS One 9(1): e83279.
35. Proctor MJ, Horgan PG, Talwar D, Fletcher CD, Morrison DS, McMillan DC (2013) Optimization of the systemic inflammation-based Glasgow Prognostic Score: A Glasgow Inflammation Outcome Study. Cancer 119(12): 2325-2332.
36. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4): 695-699.
37. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376(9754): 1741-1750.
38. Rubie C, Frick VO, Pfeil S, Wagner M, Kollmar O, Kopp B, Graber S, Rau BM, Schilling MK (2007) Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol 13(37): 4996-5002.
39. Shimazaki J, Goto Y, Nishida K, Tabuchi T, Motohashi G, Ubukata H, Tabuchi T (2013) In patients with colorectal cancer, preoperative serum interleukin-6 level and granulocyte/lymphocyte ratio are clinically relevant biomarkers of long-term cancer progression. Oncology 84(6): 356-361.
40. Son HJ, Park JW, Chang HJ, Kim DY, Kim BC, Kim SY, Park SC, Choi HS, Oh JH (2013) Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol 20(9): 2908-2913.
41. Stolfi C, Pallone F, Monteleone G (2012) Molecular targets of TRAILsensitizing agents in colorectal cancer. Int J Mol Sci 13(7): 7886-7901.
42. Van Geelen CM, de Vries EG, de Jong S (2004) Lessons from TRAILresistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7(6): 345-358.
43. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN (2006) CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203(4): 941-951.
44. Wen Y, Giardina SF, Hamming D, Greenman J, Zachariah E, Bacolod MD, Liu H, Shia J, Amenta PS, Barany F, Paty P, Gerald W, Notterman D (2006) GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1. Clin Cancer Res 12(20 Pt 1): 5951-5959.
45. Yan B, Peng Y, Li CY (2009) Molecular analysis of genetic instability caused by chronic inflammation. Methods Mol Biol 512: 15-28.
46. Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh T (2013) A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 139(3): 367-378.
47. Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M (2008) Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol 9(5): 307-311.